China Regenerative Medicine International Limited's market cap is currently HK$80.63M. The company's EPS TTM is HK$; its P/E ratio is ―; China Regenerative Medicine International Limited is scheduled to report earnings on March 26, 2025, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	HK$ 69.49M	HK$ 231.61M	HK$ 282.90M	HK$ 185.34M	HK$ 47.97M
Gross Profit	HK$ 19.42M	HK$ 37.62M	HK$ 67.73M	HK$ 45.01M	HK$ 28.92M
Operating Income	HK$ -109.12M	HK$ 8.62M	HK$ 64.59M	HK$ -128.14M	HK$ -224.14M
EBITDA	HK$ -95.40M	HK$ 14.44M	HK$ 64.66M	HK$ -122.46M	HK$ -267.63M
Net Income	HK$ -107.70M	HK$ 4.55M	HK$ 51.83M	HK$ -289.71M	HK$ -447.74M
Balance Sheet
Cash & Short-Term Investments	HK$ 3.33M	HK$ 1.85M	HK$ 9.93M	HK$ 4.77M	HK$ 308.81M
Total Assets	HK$ 185.90M	HK$ 275.91M	HK$ 259.14M	HK$ 152.49M	HK$ 553.93M
Total Debt	HK$ 50.19M	HK$ 72.01M	HK$ 35.82M	HK$ 43.19M	HK$ 311.99M
Net Debt	HK$ 46.86M	HK$ 70.16M	HK$ 25.89M	HK$ 38.43M	HK$ 302.70M
Total Liabilities	HK$ 174.10M	HK$ 172.00M	HK$ 147.41M	HK$ 207.64M	HK$ 536.30M
Stockholders' Equity	HK$ 11.79M	HK$ 103.92M	HK$ 111.73M	HK$ 58.13M	HK$ 92.83M
Cash Flow
Free Cash Flow	HK$ 6.06M	HK$ -20.25M	HK$ -3.83M	HK$ -397.74M	HK$ -29.07M
Operating Cash Flow	HK$ 6.34M	HK$ -17.65M	HK$ -3.02M	HK$ -397.74M	HK$ -23.33M
Investing Cash Flow	HK$ -262.00K	HK$ -2.59M	HK$ 9.27M	HK$ 326.96M	HK$ 406.79M
Financing Cash Flow	HK$ -7.36M	HK$ 7.32M	HK$ -1.39M	HK$ 67.37M	HK$ -393.75M

Currency in HKD

China Regenerative Medicine International Limited Earnings and Revenue History

Income Statement >

China Regenerative Medicine International Limited Debt to Assets

Balance Sheet >

China Regenerative Medicine International Limited Cash Flow

Cash Flow >

China Regenerative Medicine International Limited Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing